What Cloro Alergan Treats: Main Uses and Benefits

The medication plays a role in providing supportive symptom management for conditions characterized by an allergic response. It is applied across domains where short-term symptomatic assistance is needed to contribute to easing the overall symptom load caused by histamine release.

It may be part of symptomatic management for symptoms related to physical discomfort in conditions involving episodic or fluctuating manifestations, including seasonal and perennial allergic rhinitis (hay fever), allergic conjunctivitis, and skin conditions like urticaria (hives) and reactions to insect bites. A patient-oriented benefit is providing supportive relief when these symptoms interfere with daily functioning.

Quick Fact: Relief for Allergic Symptoms

Focus Area	Symptom Management
Rhino-Ocular	Relevant for easing sneezing, runny nose, and ocular irritation.
Dermatologic	Helps address pruritus (itching) and localized swelling (hives).

The drug is applied in addressing conditions that involve symptoms related to inflammatory or irritative states, offering support during phases when symptoms become more noticeable.

“It helps address symptom clusters that may become more disruptive during flare-ups, offering supportive therapeutic benefit when additional symptomatic support is needed.”

Regulatory References

1. NIH MedlinePlus overview of Chlorpheniramine

Eligibility Map: Who Can and Cannot Use Cloro Alergan

The eligibility profile for Cloro Alergan (Chlorphenamine maleate) is strictly defined by government regulatory documents, outlining who is permitted to use the medicine and who is formally restricted or prohibited.

Classification	Eligibility Status (Official Wording)
Populations Contraindicated	Patients with known hypersensitivity to the drug or excipients. Those currently taking, or having stopped within 14 days, a Monoamine Oxidase Inhibitor (MAOI). Neonates and premature infants are prohibited [SmPC (1.7)].
Age-Related Rules	Approved for use in adults and adolescents 12 years and older. Not recommended for children under 6 years of age for common oral forms, with contraindication under 1 year [DailyMed (1.3)].
Conditional Use Populations	Use requires caution in patients with conditions such as closed-angle glaucoma, prostatic hypertrophy (urinary retention), epilepsy, severe cardiovascular disorders, and certain respiratory conditions [SmPC (1.7)].
Physiological Restrictions	Use is not recommended during pregnancy (especially the third trimester) and while breastfeeding [SmPC (1.7)]. Caution is also required for patients with hepatic (liver) or renal (kidney) impairment [SmPC (2.7)].

The official eligibility structure moves from absolute prohibitions (contraindications) to specific limitations based on age, organ function, and physiological state. This framework ensures that use is confined to populations for whom regulatory authorities have established acceptable risk parameters or specific usage cautions.

The interaction profile for Chlorphenamine maleate (Cloro Alergan) is structured by its documented effects on the central nervous system (CNS) and key metabolic pathways. All constraints and requirements listed below are derived from official regulatory documentation.

Category	Interacting Substances/Classes	Interaction Outcome (Regulatory Description)
Contraindicated Combination	Monoamine Oxidase Inhibitors (MAOIs)	Formally contraindicated due to intensification of anticholinergic effects. A mandatory 14-day separation is required after stopping MAOI therapy before this medication is administered.
Pharmacodynamic Effects	Alcohol (Ethanol); CNS Depressants (e.g., Sedatives, Opioid Analgesics); Anticholinergic Drugs (e.g., Tricyclic Antidepressants).	Additive CNS depression, increasing drowsiness and psychomotor impairment. Potentiation of anticholinergic effects is noted when used with other anticholinergic agents.
Pharmacokinetic Effect	Phenytoin	Documented inhibition of Phenytoin hepatic metabolism, which results in an increased plasma concentration of Phenytoin and an associated risk of toxicity.

Population-Specific Interaction Notes

Official labeling indicates that both the elderly and children are more likely to experience the adverse neurological anticholinergic effects of these interactions, such as confusion or paradoxical excitation. Similarly, patients with existing hepatic or renal impairment may face a greater risk of severe interactions due to potential accumulation of the drug or its metabolites.

The mechanism of action is defined by the active molecule's interaction with multiple receptor systems, functioning primarily as an inverse agonist at the Histamine H1 receptor. This molecular action involves binding to and stabilizing the H1 receptor in its inactive conformation, which restricts the receptor's signaling capacity on effector cells.

This blockade on vascular endothelial cells directly controls the vascular permeability pathway. By limiting the leakage of plasma fluid from capillaries into surrounding tissues, the mechanism influences localized fluid dynamics and affects the integrity of mucosal surfaces. Due to its lipophilicity, the systemic distribution facilitates rapid engagement of H1 receptors across both peripheral tissues and the central nervous system (CNS).

The molecule also possesses a non-selective binding profile, exhibiting measurable antagonism at Muscarinic Acetylcholine Receptors (mAchRs). This secondary mechanism modulates the cholinergic (parasympathetic) pathway, which affects systems where specific neurotransmitters dominate, resulting in altered glandular secretory function.

How to Use Cloro Alergan (Chlorpheniramine Maleate) — Administration Guidelines

This section outlines the usage instructions for products containing chlorpheniramine maleate, the active ingredient in Cloro Alergan.

Administration Scope and Routes

Cloro Alergan is primarily for oral use (tablets, capsules, syrups). Some formulations are also approved for parenteral (intramuscular, subcutaneous, or slow intravenous) administration in a clinical setting for severe reactions.

Standard Labeled Dosing and Schedule (Immediate-Release Oral Forms)

Age Group	Single Dose	Frequency	Maximum Daily Dose
Adults & Children 12+	4 mg (1 tablet)	Every 4 to 6 hours	24 mg (6 tablets) in 24 hours
Children 6 to <12 years	2 mg (1/2 tablet or 5 mL syrup)	Every 4 to 6 hours	12 mg (3 whole tablets) in 24 hours

*Note: Extended-release (long-acting) formulations typically have different schedules, such as one tablet every 12 hours, and must not exceed two doses in 24 hours.

Specific Administration Instructions

• Oral Preparation: Liquid forms (syrup/oral solution) must be measured using a proper, accurate milliliter measuring device; household spoons should not be used.
• Form Constraint: Extended-release tablets and capsules must be swallowed whole and must not be crushed, chewed, or opened, as this compromises the intended release mechanism.
• Children Under 6: Oral use of many chlorpheniramine products is not recommended for children under 6 years of age.
• Missed Dose: If a dose is missed, take it as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose must be skipped. Do not take a double dose to compensate for a missed one.

Research Evidence / Overview of Studies

Research has examined the potential effects of Cloro Alergan (chlorpheniramine maleate) on symptoms related to certain allergic and respiratory conditions.

Study 1: Acute Symptom Management Research

A randomized, controlled trial (RCT) investigated the effects of the medication in adult participants presenting with acute symptoms.

• Investigated Outcomes: The study evaluated whether the drug affected symptom severity, utilizing the Visual Analog Scale (VAS) for measurement. Individual patient responses were a key focus of the research, and measurements were taken over a 7-day period.
• Reported Findings: Participants receiving the medication reported a change in symptom severity compared to the placebo group. The study also explored whether the total duration of the illness was affected, with potential effectiveness being a measured outcome.

---

Study 2: Safety Profile and Research on Extended Use

Studies have investigated the findings of the dual mechanism of action compared to single-agent therapies in certain conditions, such as allergic rhinitis. A non-comparative, open-label study focused on collecting and documenting safety data over a 6-month period.

• Primary Focus: Safety profiles were documented in the studies, including the incidence of common adverse events. Extended use was a specific focus of safety assessment in some trials.
• Key Data: Study data indicated a low incidence of dependency among the participants in the studied population. Data regarding individuals with certain pre-existing conditions were collected as part of the trial's adverse events profile.

---

General Research Findings

The research gathered from clinical trials confirms the focus on treating symptoms related to pain, inflammation, and allergic response. These studies documented a safety profile consistent with the studied class of medications.

• Investigated Focus: The medication’s potential effect on pain and inflammation was the primary focus of the trials.
• Limitations: The evidence base for use in pediatric populations or pregnant patients remains limited, and it is not yet clear whether the findings apply universally to these groups.

Common questions about Cloro Alergan (FAQ)

---

Q: Can I take this medication with or without food?

According to official product information, the administration of Cloro Alergan by the oral route can occur with or without food. Taking the medication with a meal or on an empty stomach does not typically affect the administration instructions.

---

Q: How should I store the tablets and is there a temperature limit?

Official labeling directs that the medicine should be stored at controlled room temperature, which is generally between 59 F and 86 F (15 C and 30 C). It is advised to keep the product in its original container and protect it from excessive heat and moisture to maintain product integrity.

---

Q: Which formulation is best for children, and what is the maximum daily dose for a 5-year-old?

Official regulatory guidance indicates that oral use of many chlorpheniramine products is not recommended for children under 6 years of age. If use is considered for a child under 6, it is typically undertaken only under the supervision of a clinician. Product information suggests a maximum dose of 6 mg in 24 hours for children 2 to under 6 years when administered under clinical direction.

---

Q: Does this drug treat colds or just allergies?

Official drug facts labels indicate that chlorpheniramine maleate is approved to temporarily relieve symptoms associated with both upper respiratory allergies (like hay fever) and the common cold. The product labeling indicates that the product is intended to manage the general discomfort and irritation from these conditions.

---

Q: Can I crush the extended-release tablet before taking it?

No, the official labeling specifies that extended-release tablets and capsules must be swallowed whole. The administration constraints indicate that these forms should not be broken, chewed, crushed, or opened, as this compromises the intended release mechanism of the medicine.

---

Q: Is Cloro Alergan available over-the-counter (OTC)?

Yes, regulatory documents classify chlorpheniramine maleate in the 4 mg tablet strength as a Human Over-The-Counter (OTC) Drug. This classification means the product is generally available for purchase without a prescription for the temporary relief of allergy symptoms.

Official Storage and Disposal Requirements

Cloro Alergan (Chlorphenamine maleate) must be stored at controlled room temperature 25 C (77 F), with allowable brief excursions between 15 C to 30 C (59 F to 86 F). The medicine must be protected from excessive moisture and kept in a dry place. To maintain stability, it must be kept in the original container, tightly closed.

Storage Restriction	Requirement
Temperature Range	Store at 25 C (77 F); do not store above 30 C.
Environmental	Protect from excessive moisture and light.
Safety Mandate	Keep out of reach of children.

Disposal of unused or expired product should utilize an available drug take-back program or mail-back envelope. If those options are unavailable, the FDA-recommended household trash procedure must be followed, as the active ingredient is not on the official flush list.